SGLT2抑制剂与其他降糖药在真实世界临床实践中的肾脏结局:日本慢性肾脏病数据库研究
基于日本慢性肾脏病数据库(J-CKD-DB)的倾向性评分1:1匹配研究,比较SGLT2抑制剂与其他降糖药对2型糖尿病合并慢性肾脏病患者肾脏结局的影响。结果显示SGLT2抑制剂组eGFR下降速度更慢(差值0.75 mL/min/1.73 m2/年),复合肾脏结局风险更低(HR 0.40,95%CI 0.26-0.61),且获益不受蛋白尿或eGFR下降速率影响。
要点
- SGLT2抑制剂显著减缓eGFR下降,年差值0.75 mL/min/1.73 m2。
- 肾脏获益不受基线蛋白尿或eGFR下降速率影响。
核心结论
- 在真实世界2型糖尿病合并慢性肾脏病患者中,SGLT2抑制剂可减缓eGFR下降并降低复合肾脏结局风险。
- SGLT2抑制剂的肾脏获益不受基线蛋白尿或eGFR下降速率影响。
研究设计与样本
- 基于日本慢性肾脏病数据库(J-CKD-DB)的全国多中心注册研究。
- 采用倾向性评分1:1匹配,SGLT2抑制剂组与其他降糖药组各1033例。
主要发现
- 基线平均年龄64.4岁,平均eGFR 68.1 mL/min/1.73 m2,蛋白尿患者578例(28.0%)。
- SGLT2抑制剂组eGFR下降斜率较其他降糖药组低0.75 mL/min/1.73 m2/年(95%CI 0.51-1.00)。
- 平均随访24个月,复合肾脏结局事件SGLT2抑制剂组30例(14/1000人年),其他降糖药组73例(36/1000人年),HR 0.40(95%CI 0.26-0.61)。
- 亚组分析显示,无论基线有无蛋白尿或eGFR下降速率如何,SGLT2抑制剂的肾脏获益一致(异质性P≥0.35)。
临床怎么用
- 对于2型糖尿病合并慢性肾脏病患者,可考虑使用SGLT2抑制剂以延缓肾功能下降。
- 使用SGLT2抑制剂时无需因基线蛋白尿状态或eGFR下降速率而限制其肾脏获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Randomized controlled trials have shown kidney-protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown. RESEARCH DESIGN AND METHODS: Using the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease. RESULTS: At baseline, mean age at initiation of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, mean eGFR was 68.1 mL/min per 1.73 m2, and proteinuria was apparent in 578 (28.0%) of included patients. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs. other drugs 0.75 mL/min/1.73 m2 per year [0.51 to 1.00]). During a mean follow-up of 24 months, 103 composite kidney outcomes occurred: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group (hazard ratio 0.40, 95% CI 0.26-0.61). The benefit provided by SGLT2 inhibitors was consistent irrespective of proteinuria and rate of eGFR decline before initiation of SGLT2 inhibitors (P heterogeneity ≥ 0.35). CONCLUSIONS: The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria.
引用
- Nagasu H, Yano Y, Kanegae H, et al. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Diabetes Care. 2021. PMID: 34593566. doi:10.2337/dc21-1081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。